high-blood-pressure-drugs
7 November 2013Europe

SPC questions referred to CJEU in Actavis v Boehringer

The UK Patents Court has referred four questions to the Court of Justice of the European Union (CJEU) seeking clarification on how the Supplementary Protection Certificate (SPC)  Regulation should be interpreted in relation to drug products made of a combination of active ingredients.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
6 July 2026   The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay.
Europe
25 June 2026   A UK judge extends a blocking order aimed at ISPs including BT, EE, and Sky, allowing the maker of Ozempic and Wegovy to add infringing sites that sell counterfeits without returning to court.
Europe
19 June 2026   The court overturns a decision granting the German-based company provisional measures and ordering a Chinese medtech rival to stop selling its device in four European countries.